BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 21396844)

  • 1. A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer.
    Whang YE; Armstrong AJ; Rathmell WK; Godley PA; Kim WY; Pruthi RS; Wallen EM; Crane JM; Moore DT; Grigson G; Morris K; Watkins CP; George DJ
    Urol Oncol; 2013 Jan; 31(1):82-6. PubMed ID: 21396844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer.
    Pezaro C; Rosenthal MA; Gurney H; Davis ID; Underhill C; Boyer MJ; Kotasek D; Solomon B; Toner GC
    Am J Clin Oncol; 2009 Aug; 32(4):338-41. PubMed ID: 19363437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erlotinib has moderate single-agent activity in chemotherapy-naïve castration-resistant prostate cancer: final results of a phase II trial.
    Nabhan C; Lestingi TM; Galvez A; Tolzien K; Kelby SK; Tsarwhas D; Newman S; Bitran JD
    Urology; 2009 Sep; 74(3):665-71. PubMed ID: 19616281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
    Tevaarwerk AJ; Kolesar JM
    Clin Ther; 2009; 31 Pt 2():2332-48. PubMed ID: 20110044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.
    Johnston S; Trudeau M; Kaufman B; Boussen H; Blackwell K; LoRusso P; Lombardi DP; Ben Ahmed S; Citrin DL; DeSilvio ML; Harris J; Westlund RE; Salazar V; Zaks TZ; Spector NL
    J Clin Oncol; 2008 Mar; 26(7):1066-72. PubMed ID: 18212337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer.
    Ross HJ; Blumenschein GR; Aisner J; Damjanov N; Dowlati A; Garst J; Rigas JR; Smylie M; Hassani H; Allen KE; Leopold L; Zaks TZ; Shepherd FA
    Clin Cancer Res; 2010 Mar; 16(6):1938-49. PubMed ID: 20215545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
    Lorenzen S; Riera Knorrenschild J; Haag GM; Pohl M; Thuss-Patience P; Bassermann F; Helbig U; Weißinger F; Schnoy E; Becker K; Stocker G; Rüschoff J; Eisenmenger A; Karapanagiotou-Schenkel I; Lordick F
    Eur J Cancer; 2015 Mar; 51(5):569-76. PubMed ID: 25694417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer.
    Sridhar SS; Hotte SJ; Chin JL; Hudes GR; Gregg R; Trachtenberg J; Wang L; Tran-Thanh D; Pham NA; Tsao MS; Hedley D; Dancey JE; Moore MJ
    Am J Clin Oncol; 2010 Dec; 33(6):609-13. PubMed ID: 20042973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer.
    Fleming MT; Sonpavde G; Kolodziej M; Awasthi S; Hutson TE; Martincic D; Rastogi A; Rousey SR; Weinstein RE; Galsky MD; Berry WR; Wang Y; Boehm KA; Asmar L; Rauch MA; Beer TM
    Clin Genitourin Cancer; 2012 Mar; 10(1):6-14. PubMed ID: 22340631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
    Burris HA; Hurwitz HI; Dees EC; Dowlati A; Blackwell KL; O'Neil B; Marcom PK; Ellis MJ; Overmoyer B; Jones SF; Harris JL; Smith DA; Koch KM; Stead A; Mangum S; Spector NL
    J Clin Oncol; 2005 Aug; 23(23):5305-13. PubMed ID: 15955900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer.
    Pietanza MC; Gadgeel SM; Dowlati A; Lynch TJ; Salgia R; Rowland KM; Wertheim MS; Price KA; Riely GJ; Azzoli CG; Miller VA; Krug LM; Kris MG; Beumer JH; Tonda M; Mitchell B; Rizvi NA
    J Thorac Oncol; 2012 May; 7(5):856-65. PubMed ID: 22722787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial.
    Ravaud A; Hawkins R; Gardner JP; von der Maase H; Zantl N; Harper P; Rolland F; Audhuy B; Machiels JP; Pétavy F; Gore M; Schöffski P; El-Hariry I
    J Clin Oncol; 2008 May; 26(14):2285-91. PubMed ID: 18467719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer.
    Liu G; Chen YH; Kolesar J; Huang W; Dipaola R; Pins M; Carducci M; Stein M; Bubley GJ; Wilding G
    Urol Oncol; 2013 Feb; 31(2):211-8. PubMed ID: 21784672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer.
    Johnston SR; Leary A
    Drugs Today (Barc); 2006 Jul; 42(7):441-53. PubMed ID: 16894399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
    Canil CM; Moore MJ; Winquist E; Baetz T; Pollak M; Chi KN; Berry S; Ernst DS; Douglas L; Brundage M; Fisher B; McKenna A; Seymour L
    J Clin Oncol; 2005 Jan; 23(3):455-60. PubMed ID: 15659491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study.
    Lara PN; Longmate J; Evans CP; Quinn DI; Twardowski P; Chatta G; Posadas E; Stadler W; Gandara DR
    Anticancer Drugs; 2009 Mar; 20(3):179-84. PubMed ID: 19396016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
    Yoshioka H; Hotta K; Kiura K; Takigawa N; Hayashi H; Harita S; Kuyama S; Segawa Y; Kamei H; Umemura S; Bessho A; Tabata M; Tanimoto M;
    J Thorac Oncol; 2010 Jan; 5(1):99-104. PubMed ID: 19898258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer.
    Gravis G; Bladou F; Salem N; Gonçalves A; Esterni B; Walz J; Bagattini S; Marcy M; Brunelle S; Viens P
    Ann Oncol; 2008 Sep; 19(9):1624-8. PubMed ID: 18467313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy.
    Agus DB; Sweeney CJ; Morris MJ; Mendelson DS; McNeel DG; Ahmann FR; Wang J; Derynck MK; Ng K; Lyons B; Allison DE; Kattan MW; Scher HI
    J Clin Oncol; 2007 Feb; 25(6):675-81. PubMed ID: 17308272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.